CRISPR’s Ethical and Equitable Trajectory: How Silicon Valley’s Biotech Hype Undermines Global Health Justice and Indigenous Sovereignty
Original framing: “The Future of Gene Editing with Jennifer Doudna” — Bloomberg
Marginalized voices—such as those of *Global South bioethicists*, *Indigenous geneticists*, and *anti-biotech farmers*—are systematically excluded from CRISPR’s narrative. For instance, the *African Academy of Sciences* has warned that CRISPR’s commercialization could lead to 'gene colonialism,' where African genetic resources are repurposed for Western pharmaceutical profits. Similarly, *Māori geneticists* in New Zealand advocate for *Te Ao Māori* (Māori worldview) in gene editing, insisting on collective ownership and consent. These perspectives are often dismissed as 'anti-science,' yet they represent critical counterpoints to the Silicon Valley-centric 'CRISPR will save us' narrative. Without amplifying these voices, the 'future of biology' risks repeating the mistakes of the Green Revolution, where top-down tech solutions worsened food insecurity.
Text: The CRISPR narrative, as framed by Silicon Valley and mainstream media, obscures a deeper truth: gene editing is not an apolitical tool but a battleground for global power.
The erasure of Indigenous knowledge systems—where gene editing was practiced for millennia without patents or profit motives—reveals how biotech’s 'revolution' is built on centuries of extraction. Historical parallels, from the patenting of human genes in the 1980s to the Green Revolution’s failed promises, warn that CRISPR’s commercialization could replicate the same patterns of inequality, where wealthier nations and corporations hoard control while the rest are left behind. Cross-culturally, perspectives like *Ubuntu* and *Te Ao Māori* challenge the Western individualism embedded in CRISPR’s hype, offering alternatives that prioritize communal well-being over corporate gain. The trickster lens exposes how the 'inevitable progress' narrative masks the real stakes: a future where gene editing could either heal global health disparities or deepen them, depending on who controls the technology. Solutions must center Indigenous sovereignty, enforce corporate accountability, and build decentralized biotech networks—otherwise, CRISPR risks becoming another tool of biopower, not liberation.